A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma
Phase of Trial: Phase I
Latest Information Update: 30 May 2018
At a glance
- Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary) ; Vocimagene amiretrorepvec-flucytosine gene therapy (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Tocagen
- 21 May 2018 Status changed from active, no longer recruiting to completed.
- 17 Oct 2017 According to a Tocagen media release, Updated Durable Response Data from this study will be presented at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
- 23 Feb 2017 According to a Tocagen media release, the U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of patients with recurrent high grade glioma (HGG). Data from this study supported the application.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History